Hanall Biopharma Company
1973
FOUNDED
PUBLIC
STATUS
301-400
EMPLOYEES
009420
STOCK SYMBOL
3
INVESTMENTS
$18.85
SHARE PRICE
(As of Friday Closing)
Description
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.
Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Delivery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Primary Office
- 6th Fl., I-Space Building, 11-10
- Sincheon-Dong
- Songpa-Gu, 138-922
- South Korea
+49 08222 0000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Hanall Biopharma Company’s full profile, request a free trial.
Hanall Biopharma Company Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $11.65 - $33.97 | $965M | $17.67 | $0.32 | 832K | 51.2M |
Hanall Biopharma Company Financials Summary
|
In Thousands,
USD |
TTM
31-Dec-2019
|
FY 2019
31-Dec-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
|---|---|---|---|---|
| Enterprise Value | 1,521,868 | 1,521,868 | 1,576,713 | 1,107,970 |
| Revenue | 93,006 | 93,006 | 83,558 | 74,279 |
| EBITDA | 15,473 | 15,473 | 3,698 | 3,431 |
| Net Income | 16,444 | 16,444 | 3,003 | 5,126 |
| Total Assets | 165,221 | 165,221 | 145,134 | 157,865 |
| Total Debt | 491 | 491 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Hanall Biopharma Company Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Hanall Biopharma Company‘s full profile, request access.
Request full access to PitchBookHanall Biopharma Company Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 19-Jul-2019 | 00000 00000 00 | 000.00 | Biotechnology | |
| 000000000 | 05-Feb-2016 | 00000 00000 00 | 00.00 | Biotechnology | 0000-000 000 |
| ImmunoMet | 01-Aug-2015 | Seed Round | 000 | Biotechnology | 0000-000 000 |
Hanall Biopharma Company Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Hanall Biopharma Company‘s full profile, request access.
Request full access to PitchBookHanall Biopharma Company Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Sung-Yon Lim | Director, Finance Planning Division | ||
| SeungKook Park Ph.D | Executive Vice President & Head, Research |
1 Former Executive
You’re viewing 2 of 3 executives. Get the full list »Hanall Biopharma Company Board Members (1)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 00000000 000 | Hanall Biopharma Company | Founder & Chairman | 000 0000 |